Be sure to catch up on the latest happenings in our spring newsletter here! Nancy Farrugia Related postsImmix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2July 23, 2026AFFIRM-AL Study Protocol AmendmentJune 23, 2022Intellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR)October 19, 2021 Previous postCARES Phase III clinical program did not meet primary endpoint in overall light chain amyloidosis population, however, demonstrated anselamimab as potential first anti-fibril therapy in kappa light chain amyloidosisNext post2026 Winter Newsletter